Clinical Trial Update: Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adding nivolumab to standard chemotherapy (cisplatin or carboplatin with gemcitabine) for recurrent or metastatic nasopharyngeal carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Phase 3 | Status: TERMINATED | Results posted: 2024-09-19